Axis Securities has given a “buy” rating for Healthcare Global Enterprises (HCG) stock, setting a target price of Rs 575. HCG, a major player in the rapidly growing cancer care industry, plans to expand its capacity significantly. With anticipated improvements in profitability, the brokerage sees a 14% upside potential from the current market price.